Colby and collaborators are clinically developing anti-inflammatory, -cancer and -autoimmune disease therapeutics. With clinical research professionals, we obtained human safety and efficacy in solid or hematological malignancies treated with proprietary cancer-specific targeted agents, using novel intralymphnode and other advanced delivery technologies resulting in significant long-term durable cancer patient remissions and potential cures. Our anti-inflammatory medicines are molecularly-targeted small molecule-, bio- and immuno-therapeutics advancing cost-effective clinical practices and favorable patient outcomes. Our molecularly targeted agents treat chronic inflammatory or hyper-proliferative diseases and are expanding clinical applications beyond cancer into targeted allergy, pain, regenerative and auto-immune medicines.
The thirteenth PMWC offers exhibition options for emerging and established companies and organizations to promote their products and services. This is an opportunity for exhibitors to interact with PMWC participants actively involved and leading the personalized medicine revolution.
PMWC 2018 Exhibitors
Exhibitions are open January 22-24 from 7:30am – 5:30pm each day. The busiest times are during designated breaks:
10:00am – 10:30am
3:30pm – 4:00pm